Peer-reviewedCC BY 4.0Frontiers in Immunology
A case report of influenza-triggered RANBP2-associated acute necrotizing encephalomyelitis in an adult successfully treated with tocilizumab
- 1Division of Internal Medicine, University Hospital of Basel
- 2Department of Neurology, University Hospital and University of Basel
- 3Multiple Sclerosis Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel
Abstract
Here, we report a rare case of a 32-year-old patient presenting with a second episode of influenza A-triggered acute necrotizing encephalomyelitis (ANE) in the context of a Ran-binding protein 2 (RANBP2) -mutation, which was diagnosed after a previous influenza-triggered ANE at the age of eleven. Despite early treatment with corticosteroids, plasmapheresis and intravenous immunoglobulins (IVIG) no meaningful clinical improvement was observed during the first 6 weeks of treatment. As interleukin-6 (IL-6) levels were elevated in both blood and cerebrospinal fluid (CSF), additional therapy with tocilizumab was initiated, leading to clinical improvement from week 11 onward.
Related
- Macrophage Activation Syndrome Associated with Adult-onset Still's Disease Successfully Treated with Plasma Exchange and Canakinumab
- Tocilizumab in refractory anti-synthetase syndrome-associated interstitial lung disease:a phenotype-stratified cohort study
- Atrophic tibial shaft nonunion in a young elite skier possibly associated with severe vitamin D deficiency and vitamin K insufficiency successfully treated with graft-free chipping and circular external fixation: a 10-year follow-up case report.
- Disease-related readmission in anti-SRP-positive immune-mediated necrotizing myopathy: Incidence and exploratory associated factors in a retrospective cohort study
- Maternal risk factors associated with neonatal necrotizing enterocolitis: a meta-analysis and systematic review.
BibTeX
@article{heusler2026case,
title = {{A case report of influenza-triggered RANBP2-associated acute necrotizing encephalomyelitis in an adult successfully treated with tocilizumab}},
author = {Marie-Anne Heusler and Sofia Sandgren and Jens Kuhle and Stephan Rüegg and Özgür Yaldizli and Cristina Granziera and Marten Trendelenburg and Severin Bausch},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1866407},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1866407/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A case report of influenza-triggered RANBP2-associated acute necrotizing encephalomyelitis in an adult successfully treated with tocilizumab
AU - Marie-Anne Heusler
AU - Sofia Sandgren
AU - Jens Kuhle
AU - Stephan Rüegg
AU - Özgür Yaldizli
AU - Cristina Granziera
AU - Marten Trendelenburg
AU - Severin Bausch
PY - 2026
DA - 2026/10/28
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1866407
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1866407/full
AB - Here, we report a rare case of a 32-year-old patient presenting with a second episode of influenza A-triggered acute necrotizing encephalomyelitis (ANE) in the context of a Ran-binding protein 2 (RANBP2) -mutation, which was diagnosed after a previous influenza-triggered ANE at the age of eleven. Despite early treatment with corticosteroids, plasmapheresis and intravenous immunoglobulins (IVIG) no meaningful clinical improvement was observed during the first 6 weeks of treatment. As interleukin-6 (IL-6) levels were elevated in both blood and cerebrospinal fluid (CSF), additional therapy with tocilizumab was initiated, leading to clinical improvement from week 11 onward.
SN - 1664-3224
ER -